Guardian Pharmacy Services, Inc.
Guardian Pharmacy Services provides technology-enabled pharmacy services to residents of long-term care facilities, including assisted living facilities, behavioral health facilities and group homes, and skilled nursing facilities. Its services include prescription dispensing, medication packaging, clinical reviews, pharmacy benefit coordination, caregiver training and compliance support. Guardian also uses proprietary analytics platforms, including Guardian Compass and GuardianShield, to support pharmacy operations and provide clinical and customer services. Guardian makes money by dispensing and supplying prescription and non-prescription medications and providing pharmacy, consulting, training and related services to residents and facilities. As of December 31, 2025, its 61 pharmacies, 54 of which are full-service, served approximately 205,000 residents in approximately 8,400 facilities across 38 states. Guardian Pharmacy Services is headquartered in Atlanta, Georgia.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $GRDN in the last 30 days.
See all $GRDN insider activity →Guardian Pharmacy Services reported Q3 Non-GAAP EPS of $0.33, beating estimates by $0.02, with revenue of $371.1M, a 1.7% year-over-year decline but $5.34M above expectations. The company's results highlight its financial performance and market positioning.
Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Guardian Pharmacy Services Reports Third Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, November 5, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financ
Guardian Pharmacy Services (GRDN) reported Q2 2026 revenue of $351.8 million, up 2% year over year, and adjusted EBITDA of $29.7 million, up 19%. Net income rose to $22.1 million. The company raised full-year 2026 guidance to $1.43 billion to $1.45 billion revenue and $129 million to $131 million adjusted EBITDA, citing underlying growth despite IRA pricing pressure.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning GRDN (Guardian Pharmacy Services, Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent GRDN coverage spans earnings, financial news and corporate actions.
Earnings beat suggests modest upside potential as the market may reprice expectations.
Raised guidance indicates stronger future earnings potential.
Guidance raise and improved profitability metrics are likely to support near-term sentiment, but H2 reported revenue is guided to decline low single digits due to IRA pricing reductions.
Raised full-year revenue guidance plus margin expansion after an EPS beat should support near-term estimates and sentiment, but IRA pricing headwinds remain a key risk.
Q2 beat and explicit full-year revenue range provide a fresh earnings-and-guidance catalyst for GRDN.
AlphAI scores every news story that mentions GRDN with an AI model for sentiment and relevance, and aggregates insider trades from Guardian Pharmacy Services, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Guardian Pharmacy Services reported Q3 Non-GAAP EPS of $0.33, beating estimates by $0.02, with revenue of $371.1M, a 1.7% year-over-year decline but $5.34M above expectations. The company's results highlight its financial performance and market positioning.
Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Guardian Pharmacy Services Reports Third Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, November 5, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation's leading long-term care ("LTC") pharmacy services companies, announced today its financ
Guardian Pharmacy Services (GRDN) reported Q2 2026 revenue of $351.8 million, up 2% year over year, and adjusted EBITDA of $29.7 million, up 19%. Net income rose to $22.1 million. The company raised full-year 2026 guidance to $1.43 billion to $1.45 billion revenue and $129 million to $131 million adjusted EBITDA, citing underlying growth despite IRA pricing pressure.
Guardian Pharmacy Services (NYSE:GRDN) rose 3.2% pre-open after reporting Q2 2026 results ahead of forecasts. Adjusted EPS was $0.29 vs $0.23 expected, and revenue was $351.8M, up 2% YoY. The company raised full-year 2026 revenue guidance to $1.43–$1.45B. Adjusted EBITDA rose 19% to $29.7M.
Guardian Pharmacy Services Inc. (GRDN) reported Q2 profit of $21.9 million, or 34 cents per share. Adjusted earnings were 29 cents versus a Zacks-surveyed analyst average of 26 cents. Revenue was $351.8 million. The company forecast full-year revenue of $1.43 billion to $1.45 billion.
Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Guardian Pharmacy Services Reports Second Quarter 2026 Financial Results; Raises Full-Year Guidance ATLANTA, August 6, 2026 – Guardian Pharmacy Services, Inc. (NYSE: GRDN), one of the nation’s leading long-term care (“LTC”) pharmacy services companies, announced toda
Guardian Pharmacy Services (NYSE: GRDN) said it opened its first Kentucky physical location, Guardian Pharmacy of Kentucky, in Lexington. The LTC pharmacy will serve assisted living, skilled nursing, behavioral health, and intellectual and developmental disability organizations statewide. The company cited increased demand and said the facility uses automation to prepare medications, led by Tom Mullaney as president.
Guardian Pharmacy Services, Inc. (GRDN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001802255 0001802255 2026-06-22 2026-06-22 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22,
Guardian Pharmacy Services, Inc. (GRDN) director Steven D. Cosler was granted 4,028 restricted stock units (RSUs) as part of a compensation package. This award, valued at $0.00 per share, increases his direct holdings to 29,012 Class A common shares. The transaction was reported in a Form 4 filing, indicating a routine equity grant rather than a market purchase or sale.
Guardian Pharmacy Services has released its financial results for the first quarter of 2026, including key financial metrics like revenue and earnings per share. The company also announced a revision to its full-year 2026 financial guidance, reflecting updated expectations based on its performance and current market conditions. This adjustment provides an updated outlook for the remainder of the year.
